Companies in the News


SAN DIEGO, April 30, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., today announced that preliminary results from an independent preclinical study showed that oncology product candidate zotatifin (eFT226) had in vitro antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The result...


Study Presented in Virtual Session at AACR Annual Meeting Provides Evidence of Potential for Zotatifin to Drug an Important Class of Oncogene Drivers

SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs)...


Vir's has two candidates that have proved highly potent in neutralising SARS-CoV-2 in live virus-cellular assays

GlaxoSmithKline PLC (LON:GSK) is to invest US$250mln into Nasdaq-listed Vir Biotechnology Inc (NASDAQ:VIR), with the two companies to work together on potential treatments for coronavirus.

It is...

Please reload